The Influence of Malnutrition, Diabetes Mellitus, and Helminth Infections on Biosignatures in Latent Tuberculosis in a South Indian Population
NCT ID: NCT04526613
Last Updated: 2025-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
626 participants
OBSERVATIONAL
2021-04-19
2026-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective:
To estimate the prevalence of malnutrition, DM, and helminth infections in people with LTBI.
Eligibility:
People age 14 65 with or without LTBI.
Design:
Participants will be screened with a medical history and physical exam focused on symptoms of active TB. Those who have TB symptoms will not take part in the study. Those who do not have TB symptoms will have a physical exam with vital signs, height, and weight. They will give blood and stool samples.
Participants will be assigned to 1 of 6 groups. They will repeat some of the screening tests. They will give urine samples. Some groups will have a chest X-ray. Some groups will have an ultrasound of the abdomen.
Participants will complete a survey about their history of smoking and drug and alcohol use.
Participants will have data collected about their nutritional status and body composition. Their skinfold thickness, ratio of waist/hip circumference, and grip strength will be measured.
Participants with DM, malnutrition, or helminth infection will be given standard of care or referred for follow-up treatment.
Participation will last up to 6 months.
...
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comorbidities and Coinfections in Latent TB
NCT04642755
Tuberculosis - Learning the Impact of Nutrition
NCT03598842
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients
NCT00265226
Tuberculosis in China
NCT01071603
Immunological Biomarkers in Tuberculosis Management
NCT04271397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Among the various risk factors that are known to play a role in promoting active TB, HIV is the most well studied and described. However, in low-HIV-endemic countries like India, other risk factors might play a more prominent role in active TB pathogenesis. These include malnutrition, diabetes mellitus (DM), and helminth infections. LTBI individuals with these comorbidities or coinfections could be at a higher risk for developing active TB than their healthy LTBI counterparts without these comorbidities. Thus, it is imperative to study the pathogenesis of TB infection and disease in these at-risk populations.
In this study, we will estimate the prevalence of severe to moderate malnutrition, uncontrolled DM, and helminth infections in LTBI-positive individuals. We will collect samples from a cohort of individuals with LTBI, those with LTBI and coexistent malnutrition, DM, or helminth coinfection, and those without any of these conditions. Individual participation may last up to 6 months. The main objective of the study is to estimate the prevalence of malnutrition, DM, and helminth infections in LTBI individuals.
Simultaneously, we will perform transcriptomic, proteomic, and metabolomic assays, including profiles in serum and urine, to determine the biosignature portfolio of these individuals. In addition, immunological assays examining cytokine/chemokine signatures as well as other immune parameters related to innate and adaptive responses will be performed to enhance the understanding of the immunological cross-talk between LTBI and malnutrition, DM, and helminth infections.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
'healthy' LTBI+ controls who are negative for all of the conditions
'healthy' LTBI+ controls who are negative for all of the listed conditions
No interventions assigned to this group
healthy LTBI negative controls with none of the above conditio
healthy LTBI negative controls with none of the above conditions
No interventions assigned to this group
LTBI+ and helminth infection (positive stool qPCR and/or serol
LTBI+ and helminth infection (positive stool qPCR and/or serology)
No interventions assigned to this group
LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)
LTBI+ and severe to moderate malnutrition (BMI \<17 kg/m2)
No interventions assigned to this group
LTBI+ and uncontrolled DM (HbA1c >8%)
LTBI+ and uncontrolled DM (HbA1c \>8%)
No interventions assigned to this group
LTBI+ with more than one of the conditions defined in groups 1
LTBI+ with more than one of the conditions defined in groups 1-3
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 14 to 65 years.
* Willingness to provide blood, urine, and stool samples for examination.
* Willingness to have samples and data stored.
* Able to provide informed consent.
Individuals are eligible for the study phase if they meet the requirements for one of the study groups, as follows:
1. LTBI+ and severe to moderate malnutrition (BMI \<17 kg/m2);
2. LTBI+ and uncontrolled DM (HbA1c \>8%);
3. LTBI+ and helminth infection (positive stool qPCR and/or serology);
4. LTBI+ with more than one of the conditions defined in groups 1 3;
5. healthy LTBI+ controls who are negative for all of the above conditions; and
6. healthy LTBI-negative controls with none of the above conditions.
Exclusion Criteria
* Two IGRA tests with indeterminate results (mitogen values \<10 IU).
* Pulmonary symptoms suggestive of TB (cough \>2 weeks in duration and/or intermittent fever \>1 week in duration and/or hemoptysis).
* Pregnant or lactating women.
* Previous treatment for LTBI.
* Anemia with hemoglobin \<8 g/dl (evaluated at the screening phase visit).
* For LTBI+ participants, clinically indicated chest X-ray positive for pulmonary TB.
* For malnourished participants, clinically indicated abdominal ultrasound positive for abdominal TB.
* Known documented cases of cancer, acquired immune deficiency syndrome, or other immunosuppressive illness.
* History of any other illness or condition which, in the investigator s judgment, may substantially increase the risk associated with the participant s participation in the protocol, or compromise the scientific objectives.
14 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas B Nutman, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute for Research In Tuberculosis, International Centers for Exel
Chennai, , India
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009 Dec;7(12):845-55. doi: 10.1038/nrmicro2236. Epub 2009 Oct 26.
Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010 Jul 1;185(1):15-22. doi: 10.4049/jimmunol.0903856.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-I-N144
Identifier Type: -
Identifier Source: secondary_id
999920144
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.